Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients

Journal of Thoracic Oncology

Volumn 8, Issue 4, 2013, Pages 461-468

  Russell, Prudence A ^a   Barnett, Stephen A ^a   Walkiewicz, Marzena ^a   Wainer, Zoe ^a   Conron, Matthew ^a   Wright, Gavin M ^a   Gooi, Julian ^a   Knight, Simon ^a   Wynne, Rochelle ^b   Liew, Danny ^a   John, Thomas ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b THE UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adenocarcinoma subtype; Mutation status; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; FISHER EXACT TEST; FOLLOW UP; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 84875405224     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182828fb8     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
2. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and genetics: Tumours of the lung, pleura, thymus and heart. In World Health Organisation Classification of Tumours. Lyon: IARC Press, 2004
3. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844-2852
4. Yim J, Zhu LC, Chiriboga L, Watson HN, Goldberg JD, Moreira AL. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol 2007;20:233-241
5. Borczuk AC, Qian F, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009;33:462-469
6. Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: A distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002;26:358-364
7. Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: A distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (
8. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003;27:101-109
9. Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg 2006;81:1988-1995
10. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: Modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827
11. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285
12. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-664
13. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification. J Thorac Oncol 2011;6:1496-1504
14. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438-1446
15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
16. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311
17. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
18. Shim HS, Lee da H, Park EJ, Kim SH. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 2011;135:1329-1334
19. Sun PL, Seol H, Lee HJ, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012;7:323-330
20. Zhang Y, Sun Y, Pan Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012;18:1947-1953
21. Goldstraw P (Ed). International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology. Orange Park, FL: Editorial Rx Press, 2009
22. John T, Kohler D, Pintilie M, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in earlystage non-small cell lung cancer. Clin Cancer Res 2011;17:134-141
23. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas: Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009;63:235-240
24. De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 2009;131:694-700
25. Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010;23:159-168
26. Ang DC, Zakowski MF, Ladayni M, et al. Characteristic morphology and immunoprofile of lung adenocarcinoma with KRAS mutations: Propensity for solid growth pattern and correlation with TTF-1 expression. Mod Pathol 2010;23:396A (suppl; abstr 1769
27. Sholl LM, Yeap BY, Iafrate AJ, et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 2009;69:8341-8348
28. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162